FTC backs FDA plan to re­move switch­ing study re­quire­ment for in­ter­change­able biosim­i­lars

The Fed­er­al Trade Com­mis­sion is back­ing a re­cent FDA pro­pos­al to of­fi­cial­ly re­move the re­quire­ment that biosim­i­lar de­vel­op­ers must run switch­ing stud­ies to ob­tain in­ter­change­abil­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER